New York City, NY -- (SBWIRE) -- 10/25/2013 -- StockMarketIntel.com issues a special report on the following stocks: Alkaline Water Company Inc (OTCBB:WTER), AT&T Inc. (NYSE:T), Janus Capital Group Inc (NYSE:JNS), A.P. Pharma, Inc. (OTCBB:APPA)
Alkaline Water Company Inc (OTCBB:WTER) declined -6.25%, trading on 1.87 million shares, to end the trade at $0.525. If we look at its trading history of the past 52 weeks, the share price suffered a low of $0.04 and was moved to the maximum level of $1.30. The stock changed hands in a range of $0.50 to $0.59, bringing its market capitalization to about $41.68 million. The Alkaline Water Company Inc., formerly Global Lines Inc, is a developer of electrolysis beverage process, packaged and branded as Alkaline84. Alkaline84 is the Company's flagship product designed to encourage daily consumption of Alkaline Water through a consumer oriented bulk delivery system.
Has WTER Found The Bottom and Ready To Move Up? Find Out Here
AT&T Inc. (NYSE:T) declined -1.84%, to complete the trading session at $34.63, with a total volume of 33.91 million shares. The stock, on average, trades on a volume of 25.18 million shares. In the past 52 weeks, the share price has not declined below $32.71 and above $39.00. It floated in a range of $34.23 to $35.01 during the last trading session, with a beta value of 0.41. Its market capitalization now moved to about $183.92 billion. AT&T Inc. (AT&T) is a holding company. AT&T is a provider of telecommunications services in the United States and worldwide. Services offered include wireless communications, local exchange services and long-distance services. AT&T operates in four segments: Wireless, Wireline, Advertising Solutions and Other. Its Wireless subsidiaries provide both wireless voice and data communications services across the United States, and through roaming agreements, in a substantial number of foreign countries.
Has AT&T Inc. Found The Bottom And Ready To Gain Momentum? Find Out Here
Janus Capital Group Inc (NYSE:JNS) recorded a gain of 4.03% and was in a range of $9.12-$9.76 before closing at $9.54. The share price hit its 52-week low of $7.68 and $10.18 was the best price. The stock completed the day with a total volume of 7.10 million shares, versus an average volume of 2.32 million shares. Janus Capital Group Inc., and its subsidiaries (JCG) provide investment management, administration, distribution and related services to financial advisors, individuals and institutional clients through mutual funds, other pooled investment vehicles, separate accounts and sub advised relationships (collectively referred to as investment products) in both domestic and international markets. JCG provides investment management competencies across a range of disciplines, including fundamental the United States and global equities (growth and value), mathematical equities, fixed income and alternatives through its subsidiaries, Janus Capital Management LLC (Janus), INTECH Investment Management LLC (INTECH) and Perkins Investment Management LLC (Perkins). JCG's investment products are distributed through three primary channels: retail intermediary, institutional and international.
What was the Moving Force behind JNS on Bullish Run? Read This Research Report
A.P. Pharma, Inc. (OTCBB:APPA) added 8.88% yesterday, bringing its market capitalization around $141.21million. The total number of shares that changed hands during the session was 3.38 million shares, as compared to average trading volume of 956,018 shares. The share price, after opening at $0.42, made a high of $0.46 and hovered above $0.42 to end the day at $0.460. A.P. Pharma, Inc. (A.P. Pharma) is a specialty pharmaceutical company developing pharmaceutical products using its Biochronomer polymer-based drug delivery platform. The Company’s lead product candidate, APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting (CINV) for patients undergoing both moderately and highly emetogenic chemotherapy and for the prevention of delayed CINV for patients undergoing moderately emetogenic chemotherapy. APF530 contains the 5-HT3 antagonist granisetron formulated in the Company’s Biochronomer drug delivery system, which allows therapeutic drug levels to be maintained for five days with a single subcutaneous injection.
For How Long APPA will fight for Profitability? Read This Trend Analysis report
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our site, or joining our email list.
Neither StockMarketIntel.com, nor its employees and affiliates are registered as investment advisors or broker/dealers in any jurisdiction whatsoever. Through use of this website viewing or using you agree to hold StockMarketIntel.com, its operators, owners, employees, and affiliates harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Readers should always do their own due diligence and consult a financial professional. StockMarketIntel.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and StockMarketIntel.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled company. Any opinions expressed on this website are statements of judgment as of the date of publication and are subject to change without further notice, and may not necessarily be reprinted in future publications or elsewhere.
Read Full disclaimer at: http://stockmarketintel.com/Disclaimer.htm
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)